Does EA IgG indicate active or recent EBV reactivation while VCA IgG indicates past infection?

The interpretation of Epstein-Barr virus (EBV) serology relies on the temporal appearance of specific antibodies. While most adults are EBV-seropositive, the presence of specific markers like Early Antigen (EA) IgG and Viral Capsid Antigen (VCA) IgG allows clinicians to distinguish between historical exposure and current viral activity.

Clinical and diagnostic evidence

• VCA IgG and Past Infection: Viral Capsid Antigen (VCA) IgG is a hallmark of past infection. It typically emerges within 2 to 4 weeks of initial exposure, often coinciding with VCA IgM. While IgM levels fade after a few months, VCA IgG persists for life in over 90% of the adult population. Its presence, especially when paired with EBV nuclear antigen (EBNA-1) IgG and a negative VCA IgM, is the standard profile for a resolved, historical infection.
• EA IgG and Active States: Early Antigen (EA) IgG is a sensitive indicator of active viral replication, showing sensitivity rates between 79.7% and 100% for identifying active disease. Unlike VCA IgG, EA IgG is generally transient. In symptomatic patients, elevated EA IgG titers correlate strongly with high EBV DNA viral loads and increased disease activity, particularly in conditions like nasopharyngeal carcinoma or rheumatoid arthritis.

Mechanistic explanations

• The Lytic vs. Latent Phase: The different antibody responses reflect the virus's life cycle. VCA IgG targets the structural proteins of the viral capsid, which remain recognized by the immune system's long-lived plasma cells during lifelong latency in memory B cells.
• Replication Markers: EA IgG targets non-structural proteins, such as p54 and p138, which are only expressed during the "lytic" phase when the virus is actively replicating its DNA. The appearance of EA IgG therefore signifies that the virus has exited its dormant (latent) state and is actively producing new virions.

Limitations and considerations

• Persistence: While EA IgG typically declines, approximately 20% of healthy individuals may show persistent EA IgG for years without clinical symptoms. Therefore, it is most reliable when interpreted as part of a full panel (VCA, EBNA, and EA).
• Reactivation Patterns: During reactivation, a classic serological shift involves a rise in VCA IgG titers alongside the new appearance or significant increase of EA IgG, often while EBNA-1 IgG remains positive.

Bottom line

The claim is strongly supported by clinical evidence: VCA IgG is a definitive marker of past exposure and lifelong immunity, whereas EA IgG is a specific indicator of the lytic phase, signaling that the virus is currently or was recently replicating.